Pharmaceuticals in the environment

Make ideas work!

Dutch approach

Sandra Mol

Tuesday 6th September 2016

© HCWH Europe 2016
Why a national approach?

- Residues of human and veterinary pharmaceuticals in the environment.
- Ecological effects (ecotox., sex change, behavioral changes are known).

Problem gets bigger in context of:
- Ageing population
- Changing climate (low flow water conditions)
- Antimicrobial resistance

EU developments:
Initial proposal of three pharmaceuticals on priority substances list (now watchlist) and European strategic approach on pharmaceuticals in the environment
What do we do (1)

• Part of the approach is a **common understanding of the (urgency of)** the problem with all stakeholders involved

• Work **jointly** on possible solutions in the chain (development and authorisation; prescription and use; disposal; (urban) waste water treatment):
  - Development ‘green pharmacy’ lengthy process and possibly not that effective(?)
  - Improvement of Environmental Risk Assessment (for ‘old’ products and also post authorisation) and accessibility of results of ERA preferably at EU level.
  - Prescription of pharmaceuticals that are less harmful for the environment?
  - Pilots on taking environment effects in account at the selection of X-ray contrast media in hospitals and mitigation measures (e.g. urine bag)
Facilitate municipalities and pharmacists with guidelines for the collection of unused medicines

(Urban) waste water treatment:
• Projects at several hospitals, now 5 hospitals with Pharmafilter-concept.
• Research on waste water treatment methods e.g. project Schone Maaswaterketen
• Hot spot analysis urban waste water treatment plants to prioritize for a decision on future measures at urban waste water treatment plants
What are the challenges

• Although the pace differs a bit between different stakeholders, a common sense of urgency is developing
• The water sector doesn’t want to be responsible for the only solution
• Communication: we don’t want to forbid certain pharmaceuticals
• Not everything can be done at a national level, improvement of Environmental Risk Assessment (also post authorisation) and accessibility of results of ERA should be done at EU level.
Pharmaceuticals in the environment

Make ideas work!

Tuesday 6th September 2016

Health Care Without Harm Europe

© HCWH Europe 2016